Next-generation sequencing (NGS) is a rapidly evolving and complex methodology that can interrogate multiple regions of genomic tumor DNA in a single assay. Many hematologic neoplasms are characterized by morphologic or phenotypic similarities but can have characteristic somatic mutations in many genes. In addition, many myeloid neoplasms lack a clonal cytogenetic finding at diagnosis (normal karyotype) but can be diagnosed and classified according to gene mutation profile. The presence and pattern of gene mutations can provide critical diagnostic, prognostic, and sometimes therapeutic information for the managing physicians.
Our facility uses state-of-the-art DNA sequencing equipment and computer analysis tools to analyze the function and structure of genomes. These capabilities allow us to monitor and explore the genome in a fraction of the time of older approaches and methodologies. For our clients, we can help predict the behavior of cancer and other diseases and forecast how they will respond to therapy, allowing for the development of more personalized treatment plans.